Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.27
+0.71 (0.34%)
AAPL  274.22
+2.08 (0.76%)
AMD  212.26
-1.58 (-0.74%)
BAC  51.73
+1.33 (2.63%)
GOOG  310.48
-0.44 (-0.14%)
META  649.20
+9.90 (1.55%)
MSFT  398.64
+9.64 (2.48%)
NVDA  196.75
+3.90 (2.02%)
ORCL  149.62
+3.48 (2.38%)
TSLA  414.55
+5.17 (1.26%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.